Dudediligence.

SELLAS Life Sciences Group, Inc

SLSNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$7.1MSep ’24−$6.7MDec ’24−$5.8MMar ’25−$6.6MJun ’25−$6.8MSep ’25−$7.7MDec ’25−$8.4MMar ’26−$9.6MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$7.6M$1.0M$0.00none on filenone on file
Gross profit$7.4M$900,000$0.00none on filenone on file
Operating income−$25.3M−$42.0M−$37.9M−$31.5M−$28.3M
Net income−$20.7M−$41.3M−$37.3M−$30.9M−$26.9M
Operating cash flow−$26.0M−$23.8M−$31.4M−$35.4M−$28.4M
Cash$21.4M$17.1M$2.5M$13.9M$71.8M
Shares outstanding15.9M21.0M32.1M74.0M153.1M